RE: RE: V.GAP developing Bladder Cancer DrugIts an annoucement to investigate the potential for development of PharmaGap's lead cancer drug GAP-107B8 in bladder cancer.
Urocidin is in PHASE 3 of testing
The current milestone payment was triggered by Urocidin™™ attaining a contractual efficacy goal from an ongoing U.S. Food and Drug Administration (FDA) Phase III registration trial. Urocidin™
I dont get anyone comparing GAP to BNC ?????? there is no reason